These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2665759)

  • 1. Additional myocardial salvage by coadministration of the epoprostenol analog taprostene to recombinant single-chain urokinase-type plasminogen activator in a canine coronary thrombosis model.
    Groves R; Schneider J; Friderichs E; Giertz H; Flohé L
    Arzneimittelforschung; 1989 Apr; 39(4):534-8. PubMed ID: 2665759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced myocardial salvage by combined treatment with recombinant single-chain urokinase-type plasminogen activator and recombinant human superoxide dismutase in a canine coronary thrombosis model.
    Fincke U; Schneider J; Friderichs E; Giertz H; Flohé L
    Arzneimittelforschung; 1988 Jan; 38(1):138-42. PubMed ID: 3365272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.
    Collen D; Stassen JM; De Cock F
    Thromb Haemost; 1987 Oct; 58(3):943-6. PubMed ID: 3124288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombolysis with recombinant human single-chain urokinase-type plasminogen activator (rscu-PA): dose-response in dogs with coronary artery thrombosis.
    Van de Werf F; Jang IK; Collen D
    J Cardiovasc Pharmacol; 1987 Jan; 9(1):91-3. PubMed ID: 2434801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.
    Ziskind AA; Gold HK; Yasuda T; Kanke M; Guerrero JL; Fallon JT; Saito T; Collen D
    Circulation; 1989 Feb; 79(2):393-9. PubMed ID: 2492455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerated intravenous dosing of recombinant tissue-type plasminogen activator causes rapid but unstable reperfusion in a canine model of acute myocardial infarction.
    Gurbel PA; Anderson RD; MacCord CS; Scott H; Serebruany V; Herzog WR
    Coron Artery Dis; 1994 Nov; 5(11):929-36. PubMed ID: 7719525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cooperative action of the prostacyclin analogue taprostene and the fibrinolytic prourokinase (r-scu-PA) in experimental artery thrombosis.
    Groves R; Schneider J; Flohé L
    Prog Clin Biol Res; 1989; 301():603-7. PubMed ID: 2508120
    [No Abstract]   [Full Text] [Related]  

  • 8. Recombinant single-chain urokinase-type plasminogen activator (rscu-PA) induces thrombolysis and systemic fibrinolysis in a canine model of coronary artery thrombosis.
    Söhngen W; Mickelson JK; Simpson PJ; Lucchesi BR
    Thromb Res; 1988 Jul; 51(1):63-74. PubMed ID: 3137691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coronary thrombolysis and infarct size reduction after intravenous infusion of recombinant tissue-type plasminogen activator in nonhuman primates.
    Flameng W; Van de Werf F; Vanhaecke J; Verstraete M; Collen D
    J Clin Invest; 1985 Jan; 75(1):84-90. PubMed ID: 4038406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The protective effect of interleukin-1 receptor antagonist on postischemic reperfused myocardium and its possible mechanism].
    Li YJ; Ding WH; Gao W; Huo Y; Hong T; Zhu RY; Ma DL
    Zhonghua Yi Xue Za Zhi; 2004 Apr; 84(7):548-53. PubMed ID: 15144587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coronary thrombolysis in man with pro-urokinase: improved efficacy with low dose urokinase.
    Kasper W; Meinertz T; Hohnloser S; Engler H; Hasler C; Rössler W; Wolf H; Welzel D; Just H; Gurewich V
    Klin Wochenschr; 1988; 66 Suppl 12():109-14. PubMed ID: 3126340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Intravenous infusion of recombinant tissue-type plasminogen activator (rt-PA) and urokinase in acute myocardial infarct: intermediate results of the G.A.U.S. study (German Activator Urokinase Study)].
    Neuhaus KL; Tebbe U; Gottwik M; Weber MA; Feuerer W; Niederer W; Haerer W; Praetorius F; Grosser KD; Huhmann W
    Klin Wochenschr; 1988; 66 Suppl 12():102-8. PubMed ID: 3126339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New thrombolytic agents in myocardial infarction].
    Charbonnier B; Lang M; Brochier M
    Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
    Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
    Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of carboxypeptidase U (TAFIa) activity improves rt-PA induced thrombolysis in a dog model of coronary artery thrombosis.
    Björkman JA; Abrahamsson TI; Nerme VK; Mattsson CJ
    Thromb Res; 2005; 116(6):519-24. PubMed ID: 16181987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endothelium and myocardial protecting actions of taprostene, a stable prostacyclin analogue, after acute myocardial ischemia and reperfusion in cats.
    Johnson G; Furlan LE; Aoki N; Lefer AM
    Circ Res; 1990 May; 66(5):1362-70. PubMed ID: 2159389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
    Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Taprostene, a stable prostacyclin analogue, enhances the thrombolytic efficacy of saruplase (recombinant single-chain urokinase-type plasminogen activator) in rabbits with pulmonary embolized thrombi.
    Schneider J
    Prostaglandins; 1991 Jun; 41(6):595-606. PubMed ID: 2052741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coronary thrombolysis by intravenous infusion of recombinant single chain urokinase-type plasminogen activator or recombinant urokinase in baboons: effect on regional blood flow, infarct size and hemostasis.
    Flameng W; Vanhaecke J; Stump DC; Van de Werf F; Holmes W; Guenzler WA; Flohe L; Collen D
    J Am Coll Cardiol; 1986 Jul; 8(1):118-24. PubMed ID: 3086416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation by heparin fragments of thrombolysis induced with human tissue-type plasminogen activator or human single-chain urokinase-type plasminogen activator.
    Stassen JM; Juhan-Vague I; Alessi MC; De Cock F; Collen D
    Thromb Haemost; 1987 Oct; 58(3):947-50. PubMed ID: 2829381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.